SEARCH WITHIN CONTENT
Mary H. Tian / Gregory R. Halverson
Citation Information : Immunohematology. Volume 25, Issue 4, Pages 174-178, DOI: https://doi.org/10.21307/immunohematology-2019-252
License : (Transfer of Copyright)
Published Online: 20-March-2020
Anti-Oka was first described by Morel and Hamilton in 1979. The Oka antigen has a very high incidence, and only eight probands that are Ok(a–) have been found; all are of Japanese heritage. In this study, we describe the generation and characterization of three novel monoclonal antibodies (Mabs), MIMA-25, MIMA-144, and MIMA-149. The reactivity of these three Mabs was compared with the original human polyclonal anti-Oka. Mice were immunized with transfected HEK cells to induce an immune response, and the spleen B lymphocytes were fused with mouse myeloma X63-Ag8.653 cells to form antibodysecreting hybridomas. The resulting Mabs were tested serologically, by flow cytometry, and by immunoblotting. The specificity of each antibody was determined after excluding specificities to common antigens in the Rh, Kell, Duffy, Kidd, MNS, Lewis, Lutheran, P1, Colton, Diego, Xga, and Dombrock blood group systems. In each case only the Ok(a–) RBC sample was nonreactive. The Mabs and the original human antiOka each have a unique pattern of reactivity when tested with enzymetreated cells; however, none were reactive by immunoblotting. We have generated three novel anti-Oka Mabs: MIMA-144 is an indirectly agglutinating IgG2b antibody, and MIMA-25 and MIMA-149 are directly agglutinating antibodies (IgM and IgA, respectively), underscoring their usefulness as typing reagents for the clinical laboratory.